0000000001308467

AUTHOR

Stefano Radellini

showing 7 related works from this author

Lacrimal glands herniation in patients with Graves’ Ophthalmopathy: an effective MRI-derived marker of disease activity

2017

Aims and objectives Methods and materials Results Conclusion Personal information References

InflammationHead and neckStaginggenetic structuresEndocrine disordersEyesMREyes Head and neck MR Diagnostic procedure Staging Endocrine disorders InflammationDiagnostic procedure
researchProduct

Diabetic foot ulcers: Retrospective comparative analysis from Sicily between two eras

2021

Aim The aim of this study was to analyze changes in the incidence, management and mortality of DFU in Sicilian Type 2 diabetic patients hospitalized between two eras, i.e. 2008–2013 and 2014–2019. Methods We compared the two eras, era1: 2008–13, era2: 2014–19. In era 1, n = 149, and in era 2, n = 181 patients were retrospectively enrolled. Results In the population hospitalized for DFU in 2008–2013, 59.1% of males and 40.9% of females died, whilst in 2014–2019 65.9% of males and 34.1% of females died. Moderate chronic kidney disease (CKD) was significantly higher in patients that had died than in ones that were alive (33% vs. 43%, p < 0.001), just as CKD was severe (14.5% vs. 4%, p <…

MaleComorbidityAntiplatelet TherapyBiochemistrySettore MED/13 - EndocrinologiaEndocrinologyMedical ConditionsOral DiseasesRetrospective StudieChronic Kidney DiseaseMedicine and Health SciencesSurgical AmputationInsulinSicilyUlcersAged 80 and overMultidisciplinaryPharmaceuticsIncidenceQRMiddle AgedDiabetic FootType 2 DiabetesHospitalizationNephrologyMedicineFemaleHumanResearch ArticleEndocrine DisordersScienceOral MedicineSurgical and Invasive Medical ProceduresSigns and SymptomsLife ExpectancyDrug TherapyDiabetes MellitusRenal DiseasesHumansMortalityRenal Insufficiency ChronicAgedRetrospective StudiesDiabetic EndocrinologyBiology and Life SciencesHormonesDiabetes Mellitus Type 2Metabolic DisordersClinical MedicinePLoS ONE
researchProduct

Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A…

2018

Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes.We selected 105 diabetic outpatients who were treated with liraglutide for at least 48 months as an add-on therapy to metformin alone (group A, n = 52) or insulin secretagogues (group B, n = 53) from diagnosis time.Although both groups showed a reduction…

Endocrinology Diabetes and MetabolismInternal MedicineAuthor CorrectionDiabetes Therapy
researchProduct

One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus

2021

Introduction: This study investigates the effects of dapagliflozin on the visceral adiposity index (VAI), lipid accumulation product (LAP), product of triglycerides and glucose (TyG) and triglycerides to HDL-cholesterol ratio (TG/HDL-C) in patients with type 2 diabetes mellitus (T2D). Methods: In this real-life study, dapaglifozin was added to metformin alone (group 1, no. 42) or insulin plus metformin (group 2, no. 58) in 100 T2D patients. Results: In group 1, after 6 months of dapaglifozin addition, a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), systolic blood pressure (SBP) (p = 0.009), diastolic blood pressure (DBP) (p = 0.012), mean fasting blood…

Visceral adiposity index.Visceral adiposity indexEndocrinology Diabetes and MetabolismLAPInternal Medicinenutritional and metabolic diseasesDapagliflozinTygCardiometabolic riskSettore MED/13 - EndocrinologiaOriginal ResearchDiabetes Therapy
researchProduct

Metabolic Profile in a Cohort of Young Sicilian Patients with Klinefelter’s Syndrome: The Role of Irisin

2022

Klinefelter’s syndrome (KS) is the main cause of hypogonadism and infertility in men and is often related to obesity, metabolic syndrome, and diabetes. The purpose of our real-life observational study was to investigate the metabolic and anthropometric parameters in a population of patients with Klinefelter syndrome compared to a group of healthy age-matched subjects. Methods. In our study, 25 consecutive Caucasian adult outpatients (age range 21–52 years, mean age 32.9 ± 12.2) with KS in testosterone replacement therapy and 30 healthy men (age range 25–45 years, mean age 32.4 ± 7.62) were studied. In both groups of subjects, anthropometric indices, lipid profile, glucose metabolic paramete…

EndocrinologyArticle SubjectEndocrine and Autonomic SystemsEndocrinology Diabetes and MetabolismKlinefelter IrisinSettore MED/13 - EndocrinologiaInternational Journal of Endocrinology
researchProduct

Papillary Thyroid Microcarcinoma: Active Surveillance Against Surgery. Considerations of an Italian Working Group From a Systematic Review

2022

IntroductionActive surveillance is considered a viable option for papillary thyroid microcarcinoma. Since the last decade of the 20th century, this method has spread from Japan to other countries, but has not yet been fully accepted and validated by the major Western Scientific Societies. In 2016, a systematic review on the results of active surveillance was published, based on two articles that showed encouraging results. Other reviews published subsequently, were mainly based on articles from the Far East. The aim of this review is to assess the most recent results published from 2017 to 2020 on this subject.Materials and MethodsA systematic literature search was performed on MEDLINE via …

Cancer Researchlymph node metastasisquality of lifeOncologyactive surveillancethyroidectomythyroid cancerpapillary thyroid microcarcinomaFrontiers in Oncology
researchProduct

One-Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus

2021

Article full text The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2021.

researchProduct